Vertex Pharmaceuticals (VRTX) Non-Current Assets (2009 - 2026)
Vertex Pharmaceuticals (VRTX) posted quarterly Non-Current Assets of $14.8 billion for Q1 2026, up 14.62% year-over-year from $12.9 billion in Q1 2025, and up 2.16% quarter-over-quarter from $14.4 billion in Q4 2025.
Vertex Pharmaceuticals (VRTX) Non-Current Assets (2009 - 2026) Analysis & Trends
Vertex Pharmaceuticals' Non-Current Assets history runs 18 years deep, the most recent figure standing at $14.8 billion for Q1 2026.
- In Q1 2026, Non-Current Assets rose 14.62% year-over-year to $14.8 billion; the TTM figure through Mar 2026 stood at $57.1 billion (up 15.5% YoY), while the FY2025 annual figure was $14.4 billion, up 11.64% from the prior year.
- Non-Current Assets for Q1 2026 stood at $14.8 billion, up from $14.4 billion in the prior quarter.
- The five-year high for Non-Current Assets was $14.8 billion in Q1 2026, with the low at $3.9 billion in Q1 2022.
- The 5-year median for Non-Current Assets is $10.6 billion (2024), against an average of $9.6 billion.
- The sharpest annual moves came in 2022 and 2024: Non-Current Assets climbed 8.36% in 2022, then soared 76.89% in 2024.
- Vertex Pharmaceuticals' Non-Current Assets stood at $4.9 billion in 2022, then soared by 74.65% to $8.6 billion in 2023, then surged by 50.67% to $12.9 billion in 2024, then climbed by 11.64% to $14.4 billion in 2025, then advanced by 2.16% to $14.8 billion in 2026.
- Business Quant data shows VRTX's Non-Current Assets at $14.8 billion in Q1 2026, $14.4 billion in Q4 2025, and $14.3 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.96 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 294.93 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.96 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 18.06 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 938.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 468.65 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | 564.41 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 14.88 Bn |
| Mar 31, 2026 | 14.75 Bn |
| Dec 31, 2025 | 14.44 Bn |
| Sep 30, 2025 | 14.29 Bn |
| Jun 30, 2025 | 13.61 Bn |
| Mar 31, 2025 | 12.87 Bn |
| Dec 31, 2024 | 12.94 Bn |
| Sep 30, 2024 | 12.44 Bn |
| Jun 30, 2024 | 11.19 Bn |
| Mar 31, 2024 | 10.63 Bn |
| Dec 31, 2023 | 8.59 Bn |
| Sep 30, 2023 | 7.03 Bn |
| Jun 30, 2023 | 6.48 Bn |
| Mar 31, 2023 | 6.01 Bn |
| Dec 31, 2022 | 4.92 Bn |
| Sep 30, 2022 | 4.44 Bn |
| Jun 30, 2022 | 4.08 Bn |
| Mar 31, 2022 | 3.89 Bn |
| Dec 31, 2021 | 3.87 Bn |
| Sep 30, 2021 | 3.77 Bn |